{"id":4564,"date":"2025-12-18T08:03:11","date_gmt":"2025-12-18T07:03:11","guid":{"rendered":"https:\/\/gevorkyan.eu\/dr-kalliwoda-presvedcive-vysledky-q3-2025-a-pozitivni-vyhled\/"},"modified":"2026-04-22T15:17:31","modified_gmt":"2026-04-22T13:17:31","slug":"dr-kalliwoda-presvedcive-vysledky-q3-2025-a-pozitivni-vyhled","status":"publish","type":"post","link":"https:\/\/www.gevorkyan.eu\/cs\/dr-kalliwoda-presvedcive-vysledky-q3-2025-a-pozitivni-vyhled\/","title":{"rendered":"Dr. Kalliwoda: P\u0159esv\u011bd\u010div\u00e9 v\u00fdsledky Q3 2025 a pozitivn\u00ed v\u00fdhled"},"content":{"rendered":"\n<p align=\"justify\"><i>&#8220;Spole\u010dnost GEVORKYAN, Inc. dos\u00e1hla v prvn\u00edch t\u0159ech \u010dtvrtlet\u00edch roku 2025 dobr\u00fdch finan\u010dn\u00edch a provozn\u00edch v\u00fdsledk\u016f a vyk\u00e1zala v\u00fdrazn\u00e9 meziro\u010dn\u00ed zlep\u0161en\u00ed ve srovn\u00e1n\u00ed s 3. \u010dtvrtlet\u00edm roku 2024. Srovn\u00e1n\u00ed s 3. \u010dtvrtlet\u00edm roku 2024 potvrzuje stabiln\u00ed finan\u010dn\u00ed zlep\u0161en\u00ed podpo\u0159en\u00e9 disciplinovan\u00fdm \u0159\u00edzen\u00edm n\u00e1klad\u016f, roz\u0161i\u0159ov\u00e1n\u00edm v\u00fdrobn\u00edch kapacit a rostouc\u00ed z\u00e1kaznickou a projektovou z\u00e1kladnou<\/i>,&#8221; uvedl Dr. Norbert Kalliwoda ve sv\u00e9m nez\u00e1visl\u00e9m analytick\u00e9m zpravodajstv\u00ed o akci\u00edch GEVORKYAN.<\/p>\n<p align=\"justify\">Spole\u010dnost Dr. Kalliwoda Research zve\u0159ejnila aktualizaci anal\u00fdzy akci\u00ed GEVORKYAN, vych\u00e1zej\u00edc\u00ed ze siln\u00fdch v\u00fdsledk\u016f za 3. \u010dtvrtlet\u00ed, kter\u00e9 byly ozn\u00e1meny dne 19. listopadu 2025: <a href=\"https:\/\/kalliwoda.com\/pdf\/GQ32025.pdf\" target=\"_blank\" rel=\"nofollow noopener\">GEVORKYAN, Inc. Komplexn\u00ed aktualizace za 3. \u010dtvrtlet\u00ed 2025<\/a>.  <\/p>\n<p>Podle analytick\u00e9 zpr\u00e1vy dos\u00e1hla spole\u010dnost GEVORKYAN v Q3 2025 tr\u017eeb ve v\u00fd\u0161i 63,5 mil. EUR (+8,7 % meziro\u010dn\u011b) a EBITDA ve v\u00fd\u0161i 23 mil. EUR (+17 % meziro\u010dn\u011b). C\u00edlov\u00e1 cena akcie je s r\u016fstov\u00fdm potenci\u00e1lem p\u0159ibli\u017en\u011b 40 %. Investi\u010dn\u00ed doporu\u010den\u00ed \u201eBUY\u201c pro GEVORKYAN, a.s., p\u016fvodn\u011b vydan\u00e9 p\u0159i zah\u00e1jen\u00ed analytick\u00e9ho pokryt\u00ed, bylo potvrzeno i v t\u00e9to aktualizaci. Analytick\u00e1 zpr\u00e1va d\u00e1le zd\u016fraz\u0148uje pokra\u010duj\u00edc\u00ed expanzi v obrann\u00e9m sektoru, mezin\u00e1rodn\u00ed r\u016fst prost\u0159ednictv\u00edm expanze v podob\u011b GEVORKYAN Force Defence Poland a prob\u00edhaj\u00edc\u00ed certifika\u010dn\u00ed procesy pro dodavatelsk\u00e9 \u0159et\u011bzce v oblasti letectv\u00ed a NATO.     <\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-4559\" src=\"https:\/\/www.gevorkyan.eu\/wp-content\/uploads\/doplnujuci-obrazok.png\" alt=\"\" width=\"940\" height=\"718\"><\/p>\n\n<p align=\"justify\"><i>Zdroj: GEVORKYAN, a.s. Comprehensive Update Q3 2025<\/i><\/p>\n<p align=\"justify\">O GEVORKYAN, a.s.<br>GEVORKYAN, a.s. je p\u0159edn\u00ed evropsk\u00e1 spole\u010dnost v oblasti pr\u00e1\u0161kov\u00e9 metalurgie, glob\u00e1ln\u00ed dodavatel pro velk\u00e9 nadn\u00e1rodn\u00ed spole\u010dnosti a jedna z nejinovativn\u011bj\u0161\u00edch spole\u010dnost\u00ed v tomto odv\u011btv\u00ed na sv\u011bt\u011b. V\u00edce informac\u00ed naleznete na <a href=\"https:\/\/www.gevorkyan.eu\/cs\/\" target=\"_blank\" rel=\"nofollow noopener\">www.gevorkyan.eu\/cs<\/a>. <\/p>\n<p align=\"justify\">O Dr. Kalliwoda Research GmbH<br>Dr. Kalliwoda Research GmbH je nez\u00e1visl\u00e1 v\u00fdzkumn\u00e1 spole\u010dnost zam\u011b\u0159uj\u00edc\u00ed se na finan\u010dn\u00ed a investi\u010dn\u00ed anal\u00fdzy. Byla zalo\u017eena v roce 2003 a poskytuje analytick\u00e9 slu\u017eby, kter\u00e9 pom\u00e1haj\u00ed investor\u016fm \u010dinit informovan\u00e1 rozhodnut\u00ed. V\u00edce informac\u00ed naleznete na <a href=\"http:\/\/www.kalliwoda.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.kalliwoda.com<\/a>.  <\/p>\n<p align=\"justify\"><b><i>Kontaktn\u00ed informace:<\/i><\/b><br>Finan\u010dn\u00ed z\u00e1le\u017eitosti: Andrej B\u00e1tovsk\u00fd, <a href=\"mailto:andrej.batovsky@gevorkyan.sk\" target=\"_blank\" rel=\"nofollow noopener\">andrej.batovsky@gevorkyan.sk<\/a><br>M\u00e9dia: Alexandra Hazuchov\u00e1, <a href=\"mailto:marketing@gevorkyan.sk\" target=\"_blank\" rel=\"nofollow noopener\">marketing@gevorkyan.sk<\/a>.<\/p>\n<p align=\"justify\"><b><i>Varov\u00e1n\u00ed:<\/i><\/b><br><i>Kalliwoda Research GmbH. Doporu\u010den\u00ed a odhady cen odr\u00e1\u017eej\u00ed nez\u00e1visl\u00fd n\u00e1zor analytika a nep\u0159edstavuj\u00ed investi\u010dn\u00ed doporu\u010den\u00ed spole\u010dnosti GEVORKYAN, Inc. Spole\u010dnost neodpov\u00edd\u00e1 za obsah ani z\u00e1v\u011bry obsa\u017een\u00e9 v analytick\u00e9 zpr\u00e1v\u011b.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Spole\u010dnost GEVORKYAN, Inc. dos\u00e1hla v prvn\u00edch t\u0159ech \u010dtvrtlet\u00edch roku 2025 dobr\u00fdch finan\u010dn\u00edch a provozn\u00edch v\u00fdsledk\u016f a vyk\u00e1zala v\u00fdrazn\u00e9 meziro\u010dn\u00ed zlep\u0161en\u00ed ve srovn\u00e1n\u00ed s 3. \u010dtvrtlet\u00edm roku 2024. Srovn\u00e1n\u00ed s 3. \u010dtvrtlet\u00edm roku 2024 potvrzuje stabiln\u00ed finan\u010dn\u00ed zlep\u0161en\u00ed podpo\u0159en\u00e9 disciplinovan\u00fdm \u0159\u00edzen\u00edm n\u00e1klad\u016f, roz\u0161i\u0159ov\u00e1n\u00edm v\u00fdrobn\u00edch kapacit a rostouc\u00ed z\u00e1kaznickou a projektovou z\u00e1kladnou,&#8221; uvedl Dr. Norbert Kalliwoda ve [&#8230;]\n","protected":false},"author":4,"featured_media":4563,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[85],"tags":[],"class_list":["post-4564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-zpravy"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/posts\/4564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/comments?post=4564"}],"version-history":[{"count":0,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/posts\/4564\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/media\/4563"}],"wp:attachment":[{"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/media?parent=4564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/categories?post=4564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gevorkyan.eu\/cs\/wp-json\/wp\/v2\/tags?post=4564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}